“Initially, ovarian cancer, melanoma, and some sarcomas are the three main targets,” says Dr. Koya, “but the clinical trial is open for patients with other cancers who meet the eligibility requirements."
Collected last week from a patient with late-stage ovarian cancer, these are not ordinary T cells; they have been altered and multiplied in the hope that when they are given back to her, they will launch a devastating attack on her cancer cells.
Historically, Japanese women were much less likely to be diagnosed with breast cancer than American women. However, as Western lifestyles become a part of everyday life in Japan, breast cancer rates are on the rise.
Because BRCA mutations are strongly linked to breast and ovarian cancer, they have been studied more widely in women than in men — and women are more likely than men to be referred by their doctors for genetic testing. But BRCA mutations are associated with many types of cancer, and men are also at risk.
We’re very excited about bringing this new series of clinical trials to our patients. The promise of outsmarting cancer and disarming its defenses by ramping up our own innate immune systems has never been more real.
Evidence strongly suggests that "light" cigarettes may actually increase a smoker’s risk of developing a type of non-small cell lung cancer called lung adenocarcinoma.
Ten years ago, patients diagnosed with advanced-stage kidney cancer had few options, and none of them were very promising. But in recent years, we have seen a revolution in kidney cancer treatment with ten new targeted drugs winning FDA approval.